期刊文献+

华海清教授运用中药治疗索拉非尼所致腹泻的经验 被引量:6

The Experience of Professor HUA Haiqing Using TCM to Diarrhea Induced by Sorafenib Tosylate
下载PDF
导出
摘要 总结华海清教授运用中药治疗索拉非尼所致腹泻的临床经验,华教授认为该病虽病位在肠,但病机当责之于脾,治疗时应兼顾对原发肿瘤的治疗,为相关研究提供借鉴。 Professor H UA Haiqing's clinical experiences of using TCM to diarrhea which was induced by sorafenib tosylate were summarized, professor Hua thought that the location was at the intestine, but the pathogenesis was the spleen we should consider the treatment for primary cancer, in order to provide evidence for related study.
作者 钱丽 华海清
出处 《西部中医药》 2013年第7期40-41,共2页 Western Journal of Traditional Chinese Medicine
关键词 原发性肝癌 索拉非尼 腹泻 中医药治疗 primary liver cancer sorafenib tosylate diarrhea TCM therapy
  • 相关文献

参考文献5

二级参考文献21

  • 1Deng-Fu Yao, Xin-Hua Wu, Yong Zhu, Gong-Sheng Shi, Zhi-Zhen Dong, Deng-Bing Yao, Wei Wu, Li-Wei Qiu and Xian-Yong Meng Nantong, China Research Center of Clinical Molecular Biology , Department of Pathology and Department of Gastroenterology , Affiliated Hos- pital of Nantong University,Department of Diagnostics , and Institute of Neurosciences , Nantong University,Nantong 226001, China.Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2005,4(2):220-226. 被引量:81
  • 2周爱萍,孙燕.多靶点抗肿瘤新药索拉非尼的研究进展[J].癌症进展,2006,4(6):529-533. 被引量:57
  • 3钱洪,金涌.以奥沙利铂为主的方案治疗晚期原发性肝癌的疗效观察[J].安徽医药,2007,11(7):593-594. 被引量:10
  • 4[2]Eisen T,Bukowski RM,Staehler M,et al.Randomized phase Ⅲ trial of sorafenib in advanced renal cell carcinoma (RCC):Impact of crossover on survival.ASCO,2006 被引量:1
  • 5[3]Bayer Pharmaceuticals Corporation.Nexavar (sorafenib)[prescribing information].West Haven:Conn,2005 被引量:1
  • 6[4]Escudier B,Szczylik C,Eisen T,et al.Randomized phase Ⅲ trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 439006) in patients with advanced renal cell carcinoma(RCC).J Clin Oncol,ASCO Annual Meeting Proceedings,2005,23:16S[Supplement],LBA4510 被引量:1
  • 7[5]Ratain MJ,Eisen T,Stadler WM,et al.Phase Ⅱ placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.J Clin Oncol,2006,24 (16):2505 被引量:1
  • 8[6]Strumberg D,Richly H,Hilger RA,et al.Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006 in patients with advanced refractory solid tumors.J Clin Oncol,2005 10,23 (5):965 被引量:1
  • 9[7]Biedrzycki BA.Renal cell carcinoma:Today's targeted therapies improving tomorrow's outcomes.ONS News.2006,21 (8Suppl):21 Available online at www.meniscus.com/eval/renal-cell-tx 被引量:1
  • 10[8]Laura Wood,et al.Advances in the treatment of renal cell carcinoma.Optimizing outcomes.2006,the Meniscus Educational Institute Available Online at www.Meniscus.Com/eval/rcc-targeted-tx 被引量:1

共引文献45

同被引文献104

引证文献6

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部